Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001203925 | SCV001375108 | uncertain significance | Noonan syndrome 9 | 2023-09-19 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 3 of the SOS2 gene. It does not directly change the encoded amino acid sequence of the SOS2 protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs758131262, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with SOS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 935354). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant is not likely to affect RNA splicing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004671250 | SCV005170310 | uncertain significance | Cardiovascular phenotype | 2024-04-09 | criteria provided, single submitter | clinical testing | The c.346-3C>T intronic variant results from a C to T substitution 3 nucleotides upstream from coding exon 4 in the SOS2 gene. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Based on the available evidence, the clinical significance of this variant remains unclear. |